Steris (STE) International Revenue Performance Explored
Explore Steris' (STE) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
STERIS: A Bump In The Road For A Reliable Name
STERIS offers a resilient, high-quality business model with some premium valuation, benefiting from hard-to-replicate sterilization networks and stable healthcare procedure volumes. Recent quarterly results included on-target 8% organic revenue growth but margin pressure from tariffs, with management raising tariff impact guidance by $10 million. STE stands to gain from stricter ethylene oxide (EtO) regulations, as compliance costs favor large, established players and will drive more outsourcing to its facilities.
STERIS plc (STE) Q3 2026 Earnings Call Transcript
STERIS plc (STE) Q3 2026 Earnings Call Transcript
STE Q3 Earnings Meet, Revenues Beat, Stock Dips in Aftermarket Trading
STERIS shares slide after hours as Q3 earnings meet estimates and revenues beat, with investors focused on gross margin contraction despite solid growth.
Compared to Estimates, Steris (STE) Q3 Earnings: A Look at Key Metrics
The headline numbers for Steris (STE) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Steris (STE) Meets Q3 Earnings Estimates
Steris (STE) came out with quarterly earnings of $2.53 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $2.32 per share a year ago.
STERIS' Q3 Earnings on Deck: What's in Store for the Stock?
STE enters Q3 earnings with revenues seen up 8% to $1.48B and EPS rising 9.1% to $2.53, supported by strength in Healthcare, AST and Life Sciences.
Is it the Right Time to Add STERIS Stock to Your Portfolio?
STE is buoyed by strong Healthcare and AST growth, solid margins and balance sheet strength, even as macro pressures and competition loom.
What Makes Steris (STE) a New Buy Stock
Steris (STE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Why Steris (STE) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Is Steris (STE) Up 0.4% Since Last Earnings Report?
Steris (STE) reported earnings 30 days ago. What's next for the stock?
Should You Hold STERIS Stock in Your Portfolio for Now?
STE posts solid AST and Healthcare growth, but currency swings and macro pressures pose rising challenges.
